

---

First published in the Government *Gazette*, Electronic Edition, on 30 April 2018 at 5 pm.

---

**No. S 234**

**MISUSE OF DRUGS ACT  
(CHAPTER 185)**

**MISUSE OF DRUGS (AMENDMENT)  
REGULATIONS 2018**

In exercise of the powers conferred by section 58(1) of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Regulations:

**Citation and commencement**

1. These Regulations are the Misuse of Drugs (Amendment) Regulations 2018 and come into operation on 1 May 2018.

**Amendment of Second Schedule**

2. The Second Schedule to the Misuse of Drugs Regulations (Rg 1) is amended —

- (a) by deleting the item “Remifentanil” in paragraph 1;
- (b) by deleting the item “3-methylthiofentanyl” in paragraph 1;
- (c) by deleting the full-stop at the end of “4-Phenylpiperidine-4-carboxylic acid ethyl ester” in paragraph 1, and by inserting immediately thereafter the following item:

“6,7,8,14-Tetrahydro-4,5- $\alpha$ -epoxy-6-methoxy-17-methylmorphinan-3-ol (also known as 3-O-demethylthebaine or Oripavine).”;

- (d) by inserting, immediately after item (1) of paragraph 10, the following item:

“(1A) Acryloylfentanyl (also known as Acrylfentanyl)”;

- (e) by inserting, immediately after item (9) of paragraph 10, the following items:

“(9A) 4-Fluoroisobutyrfentanyl (also known as 4-FIBF or pFIBF)

(9B) Furanyl fentanyl”;

- (f) by inserting, immediately after item (11) of paragraph 10, the following items:

“(11A) 3-Methylthiofentanyl

(11B) Ocfentanil”;

- (g) by inserting, immediately after item (12) of paragraph 10, the following item:

“(12A) Remifentanil”; and

- (h) by inserting, immediately after item (13) of paragraph 10, the following item:

“(13A) Tetrahydrofuranyl fentanyl (also known as THF-F)”.

### **Amendment of Fourth Schedule**

**3.** The Fourth Schedule to the Misuse of Drugs Regulations is amended —

- (a) by inserting, immediately after item (1) of paragraph 15, the following item:

“(1AA) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-butanone (also known as Dibutylone or bk-DMBDB)”;

- (b) by inserting, immediately after item (1A) of paragraph 15, the following items:

“(1AB) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)-1-butanone (also known as Eutylone)

(1AC) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one (also known as N-Ethylpentylone)”;

- (c) by inserting, immediately after item (8A) of paragraph 15, the following item:

“(8AAA) 1-(4-Bromophenyl)-2-(ethylamino)propan-1-one  
(also known as 4-Bromoethcathinone or 4-BEC)”;

- (d) by inserting, immediately after item (8AA) of paragraph 15, the following item:

“(8AB) 1-(4-Chlorophenyl)-2-(ethylamino)propan-1-one  
(also known as 4-Chloroethcathinone or 4-CEC)”;

- (e) by inserting, immediately after item (10B) of paragraph 15, the following item:

“(10C) 2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one  
(also known as 4-Methyl- $\alpha$ -ethylaminopentiophenone  
or 4-MEAPP)”;

- (f) by inserting, immediately after item (12) of paragraph 15, the following item:

“(12A) 2-(Ethylamino)-1-phenylhexan-1-one (also known as  
N-Ethylhexedrone)”;

- (g) by inserting, immediately after item (15) of paragraph 15, the following item:

“(15AA) 1-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)hexan-1-one  
(also known as 4-Fluoro-PHP)”;

- (h) by inserting, immediately after item (1) of paragraph 17, the following item:

“(1AA) N-(1-Adamantyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as FUB-APINACA or FUB-AKB48) and its fluoro positional isomers in the phenyl ring”;

- (i) by inserting, immediately after item (2B) of paragraph 17, the following item:

“(2BA) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as ADB-FUBINACA) and its fluoro positional isomers in the phenyl ring”;

- (j) by inserting, immediately after item (2D) of paragraph 17, the following item:

“(2DA) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (also known as ADBICA)”;

- (k) by deleting items (2E), (2F), (2G), (2H) and (2I) of paragraph 17 and substituting the following items:

“(2E) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-chloropentyl)-1H-indazole-3-carboxamide (also known as 5-Chloro-AB-PINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective chloro positional isomers in the pentyl group

(2F) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as AB-CHMINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers

(2G) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as AB-FUBINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring

(2H) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-AB-PINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective fluoro positional isomers in the pentyl group

(2I) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (also known as AB-PINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers

(2IA) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as PX-3 or APP-CHMINACA)”;